CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.

Metabogen is an operator of a research and development company intended to offer biomarker and personalized treatment services. The company's services include integrating metagenomic data analysis with subsequent development and clinical programs as well as specializes in the identification and improvisation of indication-related bacterial strains, enabling probiotic industry to develop novel diagnostic tests and treatments.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Shandong Dongda High-tech Huatai Pharmaceutical Co., Ltd., established on 1992-07-23, Business scope includes production,Sales:Freeze-dried powder injection,small volume injection,API(The validity period is subject to the license),food,Healthy food;Biotechnology R&D;Import and export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden.

ManRos Therapeutics was founded in 2007 by Dr. Laurent Meijer (EC Director of Research, CNRS) and Pr. Hervé Galons (EC Professor, Université Paris-Descartes), two leading specialists in cellular and molecular biology and in organic chemistry, respectively. The objectives of ManRos Therapeutics are the identification, characterization, optimization (medicinal chemistry) and preclinical & clinical development of pharmacological kinase inhibitors (some derived from marine natural products) for their use in the treatment of cystic fibrosis, polycystic kidney disease, Down syndrome and Alzheimer’s disease.

Part of Klosterfrau Healthcare Group, Sertuerner Arzneimittel is a German company located in Guetersloh focused on medicinal chemicals and botanical products. It was acquired by Lichtwer Healthcare GmbH & Co. KG on March 01, 1998.

Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases

Zhejiang Yanghe Health Management Technology Co., Ltd., established on 2021-05-20, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Health Consulting Services(Does not include medical services);Sales of Class I Medical Devices;Wholesale of sporting goods and equipment;Cosmetics Retail;Cosmetics Wholesale;marketing planning;internet sales(Except for products that require a license for sale);Domestic trade agent;General merchandise sales;Retailing of Edible Agricultural Products;Wholesale of edible agricultural products;Rehabilitation assistive device fitting service;Nursing facility services(Does not include medical services);Health Care Services(non-medical);Rural folk crafts and products,Development and management of leisure agriculture and rural tourism resources;Crop Cultivation Services;Professional cleaning,to clean,Disinfection service;business management;Housekeeping;Solid Waste Treatment;Scenic spot management;flower planting;vegetable planting;Chinese herbal medicine planting;tea planting;Urban Greening Management;building cleaning service;Catering Management;Sales of hygiene products and single-use medical products;Machinery and Equipment Leasing;Gardening Product Sales;Horticultural Products Planting;Import and export;Technology Import and Export;Chinese Medicine Clinic Services(Business activities must be filed with the competent department of traditional Chinese medicine)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:road freight transport(Does not contain dangerous goods);food sales;Main crop seed production;Forest tree seed production and management;Tobacco retail(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Guangzhou Koncen Bioscience Co., Ltd. engages in the research, development, production, and sale of blood purification products. It offers hemodialysis powder, hemodialysis concentrate, hemodialysis filters, protein A immunosorbent columns, disposable bilirubin plasma adsorbers, and hemodialysis treatment services. The company was founded by Xiao Yuan Chen on April 5, 2001 and is headquartered in Guangzhou, China.

Anhui Tongjisheng Biotechnology Co., Ltd., established on 2011-08-12, The business scope includes research and development of Dendrobium and other Dabie Mountain medicinal and edible plants,Deep processing and sales.Dendrobium decoction pieces,dendrobium flower,Dendrobium solid drink,Dendrobium tea,Dendrobium strips,Primary processing and sales of dendrobium wine and dendrobium and bletilla striata skin care products.Chinese herbal medicine protection,to develop,grow and sell;Research and development of Chinese herbal health care products,Production,Sales;Import and export of goods or technology;e-commerce(Except financial business).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

ETHRIS GmbH is a company headquartered in Planegg, Germany. The firm engages in researching and developing biotechnology. It was founded by Christian Plank and Carsten Rudolph. Carsten Rudolph is the current CEO of the firm.\nThe company says this about itself: Ethris has paved a new path from genes to therapeutic proteins using its proprietary messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilised mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines against viral infections, with the ultimate goal of improving patients? lives.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

FUJIFILM Wako Pure Chemical Corp. produces and wholesales clinical diagnostic reagents, electronic materials, and chemical products. The firm offers product information, laboratory chemicals, specialty chemicals, clinical diagnostic reagents and equipment. The company was founded in 1922 and is headquartered in Osaka, Japan.

Shuguang Hospital is a private company headquartered in Shanghai, China, that operates as a hospital.